These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30427514)

  • 1. Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis.
    Rosa Júnior M; Borges ÉI; Fonseca APA; Fiorot JL; Balarini L; Valim V
    Arq Neuropsiquiatr; 2018 Oct; 76(10):720-721. PubMed ID: 30427514
    [No Abstract]   [Full Text] [Related]  

  • 2. Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis - case report.
    Butryn M; Mewes S; Feist E; Beuing O; Müller C; Neumann J
    BMC Neurol; 2021 Jun; 21(1):228. PubMed ID: 34157987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Slow Desensitization to Tocilizumab in a 15-Year-Old Patient.
    Cansever M; Şahin N; Dursun I; Geyik C; Düşünsel R; Bektaş Kut F; Tahan F
    J Investig Allergol Clin Immunol; 2018 Dec; 28(6):436-438. PubMed ID: 30530397
    [No Abstract]   [Full Text] [Related]  

  • 4. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis.
    Nakamura H; Sugai T; Kato M; Hatanaka KC; Atsumi T
    Clin Exp Rheumatol; 2017; 35(1):174. PubMed ID: 28079502
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis.
    Tozawa Y; Fujita S; Abe S; Kitamura K; Kobayashi I
    Pediatr Int; 2015 Apr; 57(2):307-10. PubMed ID: 25868948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
    Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
    Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
    [No Abstract]   [Full Text] [Related]  

  • 8. Guidance on using tocilizumab for juvenile idiopathic arthritis.
    Yokota S; Imagawa T; Takei S; Murata T; Tomiita M; Itoh Y; Fujikawa S; Mori M
    Mod Rheumatol; 2011 Dec; 21(6):563-71. PubMed ID: 21597951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for the treatment of juvenile idiopathic arthritis.
    Decelle K; Horton ER
    Ann Pharmacother; 2012 Jun; 46(6):822-9. PubMed ID: 22589451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab for systemic juvenile idiopathic arthritis.
    De Benedetti F
    N Engl J Med; 2013 Mar; 368(13):1256-7. PubMed ID: 23534566
    [No Abstract]   [Full Text] [Related]  

  • 11. Tocilizumab for systemic juvenile idiopathic arthritis.
    Hagino N; Yamaguchi K; Ohara Y
    N Engl J Med; 2013 Mar; 368(13):1256. PubMed ID: 23534567
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis.
    Quesada-Masachs E; Caballero CM
    J Rheumatol; 2017 Feb; 44(2):260-261. PubMed ID: 28148759
    [No Abstract]   [Full Text] [Related]  

  • 13. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
    Herlin T
    Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Ann Rheum Dis; 2013 Apr; 72(4):627-8. PubMed ID: 23204515
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
    Shimizu M; Hamaguchi Y; Ishikawa S; Ueno K; Yachie A
    Mod Rheumatol; 2015; 25(6):972-3. PubMed ID: 25496406
    [No Abstract]   [Full Text] [Related]  

  • 16. Posterior reversible encephalopathy syndrome in acute pancreatitis.
    Compagnone C; Bellantonio D; Pavan F; Tagliaferri F; Barbagallo M; Fanelli G
    Minerva Anestesiol; 2016 Nov; 82(11):1236-1237. PubMed ID: 27270074
    [No Abstract]   [Full Text] [Related]  

  • 17. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
    Tappeiner C; Heinz C; Ganser G; Heiligenhaus A
    J Rheumatol; 2012 Jun; 39(6):1294-5. PubMed ID: 22661419
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL; Wimalasundera S; Hsu JC; Douglass W; Wells C; Penades IC; Cuttica R; Huppertz HI; Joos R; Kimura Y; Milojevic D; Rosenkranz M; Schikler K; Constantin T; Wouters C
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):57. PubMed ID: 31438986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete clinical remission with tocilizumab in two infants with systemic juvenile idiopathic arthritis: a case series.
    Maritsi DN; Onoufriou M; Vartzelis G; Eleftheriou D
    Scand J Rheumatol; 2017 Jan; 46(1):75-76. PubMed ID: 27218706
    [No Abstract]   [Full Text] [Related]  

  • 20. Atypical presentation and imaging features of postpartum posterior reversible encephalopathy syndrome.
    Vitucci A; Lojacono A; Gatti E; Prefumo F; Fratelli N
    J Obstet Gynaecol; 2019 Apr; 39(3):412-414. PubMed ID: 30226402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.